LUND, Sweden, April 17, 2026 (GLOBE NEWSWIRE) -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces that it ...
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that ...
On the one hand, more efficient reprogramming could, if poorly controlled, increase the chance of generating cells with unintended self renewal properties. On the other, precise control over gene ...
Scientists at the MRC Laboratory of Medical Sciences (LMS) have discovered a DNA-based “dimmer switch” that regulates the activity of a critical developmental gene, Cdx2. This work could pave the way ...
CGTE researchers Dr. Stelios Andreadis, center director, and Dr. Kirk Personius are lead co-authors of a paper in the October 24th edition of Nature Communications. This study describes experiments ...
Kazia Therapeutics expands oncology platform with first-in-class SETDB1 inhibitor drug development platform: Sydney, Australia Wednesday, April 15, 2026, 15:00 Hrs [IST] Kazia The ...
Epigenetics, the dynamic regulation of genetic expression, involves complex molecular mechanisms. While the process of gene silencing by methylating the H3K27 position in histones is understood, not ...